Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Completed · Phase 3 · NCT06354660
Conditions: Diabetes Type 2
At a glance
- Research payments reported, 2025
- $3.3M
- U.S. investigators named
- 37
- Sites paid
- 35
- Planned or actual enrollment
- 537
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Retatrutide (drug), Placebo (drug)
- Dates
- Started 2024-04-10; completion 2026-02-20
- Results posted
- Not yet
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
From ClinicalTrials.gov, last updated 2026-03-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3.3M in research payments for this study in 2025 (73 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jitendra Sharma, M.B.B.S Neurology · Birmingham, AL
- Girish J. Karamchandani, DO Internal Medicine · Tucson, AZ
- Jeffrey London, MD Internal Medicine · West Hills, CA
- Martha G. Navarro, MD Family Medicine · Redondo Beach, CA
- Lazaro R. Diaz-nunez, MD Family Medicine · Naples, FL
- Manuel F. Fernandez, MEDICAL DOCTOR General Practice · Miami, FL
- Senan Sultan, M.D. Endocrinology & Diabetes · Jacksonville, FL
- Eduardo Torres, MD Family Medicine · Winter Haven, FL
- Jean J. Philippe-dambreville, MD Internal Medicine · Atlanta, GA
- Michael R. Cox, MD Internal Medicine · Topeka, KS
- Ehab Sorial, M.D. Internal Medicine · Fall River, MA
- Zachary A. Sporn, MD Student in an Organized Health Care Education/Training Program · Boston, MA
- Timothy W. Jennings, D.O. Family Medicine · Maryland Heights, MO
- Aubrey M. Remmers, M.D. Family Medicine · Missoula, MT
- John C. Parker, M.D. Endocrinology & Diabetes · Wilmington, NC
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Joseph Heether, MD General Surgery · Hamilton, NJ
- Preet Randhawa, M.D Cardiology · Linden, NJ
- Robert E. Dunn, MD Cardiac Electrophysiology · Cleveland, OH
- Devora Lichtman, MD Internal Medicine · Cleveland, OH
- Paul J. Opsahl, MD Family Medicine · Waynesville, OH
- Ernest C. Lee, M.D., M.P.H. Family Medicine · Tinker Afb, OK
- Richard A. Cook II, MD Family Medicine · Uniontown, PA
- Elizabeth A. Barranco, MD Internal Medicine · Ponce, PR
- Luis A. Pagan, MD General Practice · Dorado, PR
- Edward M. Newton, MD Family Medicine · Charleston, SC
- Felix O. Berglund, MD Cardiology · Nashville, TN
- Stephan C. Sharp, MD Endocrinology & Diabetes · Nashville, TN
- Pedro Velasquez, MD Endocrinology & Diabetes · Memphis, TN
- Chad Crystal, M.D. Emergency Medicine · Palestine, TX
- Alex Guevara JR., D.O. Family Medicine · Fort Worth, TX
- Wasim A. Haque, M.D. Endocrinology & Diabetes · Flower Mound, TX
- Dan Lender, MD Endocrinology & Diabetes · Rockwall, TX
- Eduardo D. Luna, M.D. Endocrinology & Diabetes · Edinburg, TX
- Michelle D. Welch, MD Endocrinology & Diabetes · Shavano Park, TX
- Nabil S. Andrawis, M.D. Internal Medicine · Burke, VA
- Jonathan M. Staben, MD Family Medicine · Cheney, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ezy Medical Research Co $444,574
- Ark Clinical Research LLC $251,135
- San Fernando Valley Health Institute LLC $243,375
- Dorado Medical Complex Inc $220,498
- Clinical Research Professionals LLC $196,344
- Eastside Research Associates LLC $154,950
- Piedmont Medical Research Associates Inc $154,192
- Phoenix Clinical Trials LLC $140,624
- Velocity Clinical Research Inc $134,926
- New Horizon Research Center $129,520
- Valley Institute of Research LLC $121,964
- Cotton Oneil Msd of Stormont Vail Healthcare $102,045
- Tucson Clinical Research Institute $102,011
- Consano Clinical Research LLC $88,413
- Texas Valley Clinical Research LLC $86,313
- Boeson Research LLC $82,800
- Clincial Research of Central Florida $82,626
- Preferred Primary Care Physicians Inc $79,078
- Burke Internal Medicine Inc, DBA Manassas Clinical Research Cent $78,467
- Providence Health PArtners $76,703
- N Texas Diabetes and Endocrine $47,393
- Northeast Research Institute $45,382
- Lifedoc Research PLLC $35,933
- Trinity Research LLC $33,035
- Clinical Research Associates Inc $31,707
- Delricht LLC $30,746
- Ponce School of Medicine $28,936
- Deaconess Medical Center, WA $11,130
- Clinical Research Philadelphia LLC $9,478
- Neccr Prima Care Research LLC $6,120
- $2,960
- Rheumatology Center of Houston $1,352
- Cleveland Clinic, OH $1,106
- Gemini Testing Enterprises Inc $331
- Clinical Research of Philadelphia LLC $300
- Dallas Diabetes and Endo Research Center PA $105
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.